Skip to main
PVLA
PVLA logo

PVLA Market Capitalization Overview

Market Cap: $292.54M as of Jul 11, 2025

$292.54M
Past Month+$2.55M (0.88%)
As of Jul 11, 2025, PVLA has a market capitalization of $292.54M. Over the past 30 days, its market cap has decreased by -9.82%, while in the last 12 months, it has increased by 193.11%.

Market capitalization represents the total value of Palvella Therapeutics Inc as perceived by the stock market. It is calculated by multiplying the current stock price by the total number of outstanding shares.

PVLA Market Cap Formula = Stock Price * Shares Outstanding

The market cap of PVLA helps investors assess the company's size and compare it with competitors for better investment decisions.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

PVLA Market Cap History

DateMarket CapChange
Jul 1, 2025$250.64M-9.82%
Jun 2, 2025$277.95M+4.71%
May 1, 2025$265.45M+0.28%
Apr 1, 2025$264.72M+20.66%
Mar 3, 2025$219.38M+50.73%
Feb 3, 2025$145.55M+45.83%
Jan 2, 2025$99.81M+489.20%

PVLA End of Year Market Cap History

DateMarket CapChange
2025$292.54M+193.11%
2024$99.81M

FAQs About Palvella Therapeutics Inc (PVLA) Market Cap

As of Jul 11, 2025, the market capitalization of PVLA is $292.54M. Market cap represents the total value of a company’s outstanding shares and is a key indicator of its size in the stock market.

In the last 30 days, Palvella Therapeutics Inc’s market capitalization has increased by 0.8800%, changing from $289.99M to $292.54M as of Jul 11, 2025.

In the last 3 months, Palvella Therapeutics Inc’s market capitalization has increased by —, changing from – to – as of –.

In the year 2024, Palvella Therapeutics Inc’s market capitalization increased from – in January to $99.81M in December, reflecting a — change.

Palvella Therapeutics Inc (PVLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.